MDX-1097 (formerly called IST-1097, now called KappaMab) is a monoclonal antibody therapy being developed by the Australian biotechnology company HaemaLogiX Ltd for the treatment of multiple myeloma.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.